Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Rajdeep is an accomplished business leader with a strong techno-commercial background in the healthcare and diagnostic sector
India’s pharmaceutical sector stands at a pivotal inflection point
Pravesh brings with him over 29 years of experience in leading complex manufacturing operations and driving operational excellence
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
The company previously completed a $150 million venture investment, acquisition, and recapitalization
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
Subscribe To Our Newsletter & Stay Updated
